This site is intended for U.S. healthcare professionals.
Examine data from the HOPE and HOPE-KIDS 1 trials
View dosing schedule and adjustments
Discover the YourSource™ program
Oxbryta is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older.
This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).